Adropin

What is Adropin?

Adropin is a secreted peptide hormone of 76 amino acids, encoded by the ENHO ("Energy Homeostasis Associated") gene. It was first identified in 2008 as a liver- and brain-derived factor regulating energy homeostasis and macronutrient adaptation. Since then, research has expanded to show roles in glucose metabolism, insulin sensitivity, endothelial function (partly via eNOS upregulation), and cardiac fuel metabolism. Adropin is primarily a research molecule and biomarker — it is not available as a therapeutic product, has no clinical trial program as a drug, and is not FDA-approved for any indication. Its relevance to the wellness and peptide community is largely aspirational: circulating adropin levels correlate with metabolic health, but exogenous adropin has not been validated in humans.

What Adropin Is Investigated For

Adropin's research footprint is dominated by its role as a metabolic biomarker — low circulating adropin consistently associates with obesity, type 2 diabetes, NAFLD, and cardiovascular disease, while higher levels correlate with better cardiovascular outcomes. The strongest biology is mechanistic: adropin upregulates endothelial nitric oxide synthase (eNOS) via VEGFR2–PI3K–Akt and VEGFR2–ERK1/2 pathways, improves insulin sensitivity in rodent models, and has neuroprotective effects in ischemia-reperfusion injury. What adropin is not: a validated therapeutic. There is no approved adropin drug, no registered clinical trial of exogenous adropin for any indication, no established dose, and no human safety data. The "take adropin for metabolic health" framing that appears in peptide marketing extrapolates from biomarker correlations and preclinical data — real signals, but not the same as proven human therapeutic effect.

How It Works

Adropin is a hormone your liver and brain make to help regulate energy balance, blood sugar, and blood vessel function. People with obesity, diabetes, or heart disease tend to have lower adropin levels, and animal studies show that giving adropin improves insulin sensitivity and blood vessel health. But no one has successfully turned adropin into a drug — it's currently a research marker, not a treatment.

Adropin is a 76-amino-acid secreted peptide encoded by the ENHO gene, expressed primarily in liver and brain and detectable in serum, kidney, heart, pancreas, small intestine, and vascular endothelium. In endothelial cells, adropin upregulates eNOS expression through the VEGFR2–PI3K–Akt and VEGFR2–ERK1/2 pathways, increasing nitric oxide bioavailability and vasodilation. In hepatocytes and skeletal muscle, adropin modulates fatty acid oxidation, glucose uptake, and insulin sensitivity — overexpression in diet-induced obese mice improves insulin sensitivity and reduces diabetes markers. In the brain, adropin tightens brain endothelial tight junctions (reducing paracellular permeability) under ischemic conditions, a mechanism implicated in its neuroprotective effect in stroke models. A candidate receptor (GPR19) has been proposed but not universally accepted; the full receptor pharmacology is still being worked out. Adropin levels are regulated by nutritional state (rising with fat intake, falling with energy excess in chronic overfeeding) and modulated by estrogen in humans.

Evidence Snapshot

Forms & Administration

Adropin is not available as an approved therapy. Research applications use recombinant adropin administered parenterally in animal studies. For clinical relevance, the practical path to raising endogenous adropin is lifestyle-mediated — weight loss, improved nutritional patterns, and exercise all tend to raise circulating levels.

Common Questions

Safety Profile